Loading stock data…
KRRO
$13.57+0.08 (+0.59%)
Market ClosedLast close May 1
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Korro Bio, Inc. in the Healthcare sector is trading at $13.57. The stock is currently near its 52-week low of $5.20, remaining 27.4% below its 200-day moving average. Technical signals show neutral RSI of 49 and bearish MACD signal, explaining why KRRO maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.57
Potential Upside
5%
Whystock Fair Value$14.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead produ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$201.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-227.96%
Volume
Today's trading volume
74,498
Recent News
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2?
Insiders aggressively bought these stocks, signaling confidence in their operations. The question is whether others think the same.
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) delivered earnings and revenue surprises of -175.08% and -13.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?
United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -6.99% and -1.53%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?